Multicenter, open-label, phase 1, cohort dose escalation study to determine the MTD on both QD and BID schedules.

Multicenter, open-label, phase 1, cohort dose escalation. The study will open with the QD schedule, with initiation of the BID schedule occurring after observation of clinically significant related toxicity >/= grade 2 in the QD schedule.

Dosing will be initiated on Day 1 with daily dosing (either QD or BID) continuing for 21 days.

Patients may continue to receive OSI-906 until one of the following occurs: disease progression, adverse event requiring withdrawal, failure to recover from toxicity despite a 14-day dosing interruption, medical or ethical reasons, patient request, or patient death.

• Experimental: Once per day
• Experimental: Twice per day

Inclusion Criteria:

• Histologically or cytologically documented malignancy that is now advanced and/or metastatic and refractory to established forms of therapy or for which no effective therapy exists.
• Age >/= 18 years, ECOG PS 0-2, life expectancy >/= 12 weeks
• Prior chemotherapy is permitted provided that a minimum of 3 weeks has elapsed. Prior tyrosine kinase inhibitor therapy is permitted. Patients must have recovered from any treatment-related toxicities (with some exceptions) prior to registration.
• Prior hormonal therapy is permitted provided it is discontinued prior to registration (with the exception of prostate cancer patients who have been on hormone therapy for at least 3 months).
• Prior radiation therapy is permitted provided that patients have recovered from the toxic effects. A minimum of 21 days must have elapsed unless the radiotherapy was palliative and nonmyelosuppressive.
• Fasting glucose </= 125 mg/dL (7 mmol/L) at baseline
• Potassium, calcium, and magnesium must be within normal limits (WNL). Electrolyte abnormalities will be permitted if they are not clinically significant and if treatment for the abnormality is initiated prior to Day 1.
• ANC >/= 1.5 x 10^9/L, PLT >/= 100 x 10^9/L; bilirubin </= 1.5 x upper limit of normal (ULN), AST and ALT </= 2.5 x ULN; creatinine </= 1.5 ULN
• Accessible for repeat dosing and follow-up, including pharmacokinetic sampling.
• Patients must practice effective contraceptive measures throughout the study.
• Provide written informed consent.

Exclusion Criteria:

• History of any kind of stroke.
• History of any psychiatric condition that might impair the patient's ability to provide informed consent or participate.
• History of allergic reaction attributed to a similar compound as study drug.
• Any type of active seizure disorder.
• Previously diagnosed brain metastases.
• Concurrent anticancer therapy.
• Active or uncontrolled infections of serious illnesses or medical conditions that could interfere with participation.
• Pregnant or breast-feeding females.
• Documented history of diabetes mellitus.
• Use of drugs with a risk of causing QT interval prolongation within 14 days prior to Day 1 and while on study.
• Use of glucocorticoids within 14 days prior to Day 1 and while on study.
• History of significant cardiac disease unless well controlled (includes 2nd/3rd degree heart block, ischemic heart disease, QTc > 450 msec, poorly controlled hypertension, and congestive heart failure of New York Heart Association (NYHA) Class II or worse